Crohn-betegség: vizsgálatok itt: Dél-Korea

In Dél-Korea 30 Also abroad 422

30 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.

3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Ansan-si, Busan, Daegu, Daejeon, Dongjak-gu, Haeundae-gu, Seoul, Suwon, Wŏnju
Életkor
16 év to 80 év
People
1200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
3. fázisTaking people
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Busan, Daegu, Seoul
Életkor
2 év to 17 év
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00
3. fázisTaking people
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Where
Seoul
Életkor
3 év to 64 év
People
196 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00
2/3. fázisTaking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Busan, Daegu, Daejeon, Dongdaemun-gu, Seongnam-si, Seoul, Suwon
Életkor
18 év and over
People
1092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
3. fázisTaking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Busan, Daejeon, Ganggu, Seoul
Életkor
18 év and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
2. fázisTaking people
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Where
Busan, Daegu, Seoul, Wŏnju
Életkor
18 év to 75 év
People
268 worldwide
Run by
Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00
3. fázisTaking people
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Ansan-si, Daegu, Gwangju, Seoul
Életkor
16 év to 80 év
People
425 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819891 · EU 2024-513054-30-00
3. fázisTaking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Ansan-si, Busan, Daegu, Daejeon, Gwangju, Seoul, Suwon
Életkor
16 év to 80 év
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
3. fázisTaking people
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Busan, Gwangju, Seoul
Életkor
16 év to 80 év
People
751 worldwide
Run by
Sanofi
See details and how to joinNCT07184944
3. fázisTaking people
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Daegu, Seoul
Életkor
2 év to 17 év
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00
3. fázisTaking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Busan, Daegu, Daejeon, Gangwon-do, Guri-si, Seoul
Életkor
16 év to 80 év
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
3. fázisTaking people
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Where
Daegu, Seoul
Életkor
2 év to 17 év
People
70 worldwide
Run by
Takeda
See details and how to joinNCT06405087 · EU 2023-508804-39-00
3. fázisTaking people
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Where
Deagu, Seoul
Életkor
2 év to 19 év
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT04844606
3. fázisTaking people
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Where
Busan, Daegu, Seoul
Életkor
2 év to 17 év
People
90 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00
2. fázisTaking people
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Where
Busan, Daegu, Daejeon, Seoul
Életkor
18 év to 75 év
People
590 worldwide
Run by
AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00
1. fázisTaking people
A Phase 1 Study of ATORM-C in Patients With Crohn's Disease
Where
Seoul
Életkor
19 év to 80 év
People
18
Run by
ORGANOIDSCIENCES LTD.
See details and how to joinNCT07822087
3. fázisTaking people
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Where
Daegu, Seoul
Életkor
2 év to 17 év
People
70 worldwide
Run by
Takeda
See details and how to joinNCT06100289 · EU 2023-503188-40-00
3. fázisTaking people
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Where
Busan, Daegu, Daejeon, Seoul, Suwon
Életkor
18 év to 65 év
People
396 worldwide
Run by
Takeda
See details and how to joinNCT06227910 · EU 2023-509391-42-00
2. fázisTaking people
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Where
Haeundae, Wŏnju
Életkor
18 év to 75 év
People
192 worldwide
Run by
Takeda
See details and how to joinNCT06764615 · EU 2024-518914-18-00
3. fázisTaking people
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Where
Daegu, Incheon, Seoul
Életkor
2 év to 17 év
People
240 worldwide
Run by
Takeda
See details and how to joinNCT05442567 · EU 2023-509046-36-00
3. fázisTaking people
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Where
Daegu, Incheon, Seongnam, Seoul
Életkor
2 év to 17 év
People
120 worldwide
Run by
Takeda
See details and how to joinNCT04779320 · EU 2023-509045-13-00
No phaseTaking people
Predictors of Prognosis in IBD Patients
Where
Seongnam-si
Életkor
18 év and over
People
100
Run by
Seoul National University Bundang Hospital
See details and how to joinNCT05653011
No phaseTaking people
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Where
Goyang-si
Életkor
18 év and over
People
600
Run by
Takeda
See details and how to joinNCT05428345
No phaseCsak meghívásos
Research for the Precision Medicine in the Treatment of Inflammatory Bowel Disease
Where
Seoul
Életkor
10 év and over
People
2000
Run by
Seoul National University Hospital
See details and how to joinNCT07166588
No phaseTaking people
SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease
Where
Seoul
Életkor
10 év and over
People
500
Run by
Seoul National University Hospital
See details and how to joinNCT07011979